Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lopinavir ritonavir

The initial search for an inhibitor of the SARS 3CL protease focused on preexisting drugs and compounds, some tested empirically and others selected based on modeling. The HlV-1 PI nelfinavir and lopinavir/ritonavir have been considered, with the latter actually used clinically in SARS CoV-infected subjects. The rhi-novirus inhibitor ruprintrivir and related compounds have also been tested (reviewed in Fear et al. 2007). However, in the absence of any elements of specificity, these preexisting compounds would be expected to have low potency. [Pg.102]

Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177 Johnson M (2006) Response to Atazanavir/ritonavir versus lopinavir/ritonavir equivalent or different efficacy profiles by HUl. AIDS 20 1987... [Pg.105]

Lopinavir/ritonavir, and abacavir or stavudine or tenofovir or didanosine, and lamivudine or emtricitabine... [Pg.1259]

Lopinavir + ritonavir LPV 200 mg + 2 tablets or 5 ml Use with caution in patients Take with food (AUC Nausea, vomiting, diarrhea CYP3A4 inhibitor... [Pg.1264]

Women of reproductive potential prescribed efavirenz should be counseled on its potentially teratogenic effects and the importance of birth control. Additionally, nevirapine, nelfinavir, ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir have been shown to decrease the concentrations of estrogens and/or progestins in oral contraceptives, which could lead to failure.2 For patients prescribed these drugs, barrier forms of contraception are preferred to prevent pregnancy. DepoProvera may be... [Pg.1267]

TC, lamivudine ABC, abacavir APV, amprenavir AST, aspartate aminotransferase ALT, alanine aminotransferase ATV, atazanavir CBC, complete blood cell count D/C, discontinue ddl, didano-sine d4T, stavudine EFV, efavirenz FTC, emtricitabine P1BV, hepatitis B virus F1CV, hepatitis C vims HIV, human immunodeficiency virus IDV, indinavir IV, intravenous LFT, liver function tests LPV/r, lopinavir + ritonavir NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor PT, prothrombin time T.bili, total bilirubin TDF, tenofovir disoproxiI fumarate TPV, tipranavir ULN, upper limit of normal ZDV, zidovudine. [Pg.1271]

Lopinavir/ritonavir or atazanavir/ritonavir and (zidovudine or fosamprenavir/ritonavir or tenofovir) and (lamivudine or emtricitabine). [Pg.1275]

Azalides azithromycin Azoles fluconazole, itraconazole, ketoconazole, and voriconazole Macrolides erythromycin, clarithromycin Protease inhibitors amprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, and saquinavir Quinolones ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin. [Pg.396]

Lopinavir/ritonavir (twice daily) (coformulated) (All) Alternatives Atazanavir (Bll)... [Pg.452]

Fewer head-to-head data with oncedaily fosamprenavir-ritonavir and lopinavir ritonavir, as well as saquinavir (Invirase) + ritonavir... [Pg.452]

Current recommendations for treating HIV infection advocate a minimum of three antiretroviral agents. The typical regimen consists of two NtRTIs and either a ritonavir-boosted PI or NNRTI. The dual NtRTI backbone should include tenofovir plus emtricitabine (coformulated as Truvada) or zidovudine plus lamivudine (coformulated as Combivir). Abacavir plus lamivudine is an alternative. Recommended initial NtRTIs include atazana-vir-ritonavir, lopinavir-ritonavir, or fosamprenavir-ritonavir. Efavirenz is the recommended NNRTI except for women who plan to become pregnant or who do not have adequate contraception. [Pg.454]

L. Gavard, S. Gil, G. Peytavin, P.F. Ceccaldi, C. Ferreira, R. Farinotti, and L. Mandelbrot. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Ami Obstet Gynecol. 195 296-301 (2006). [Pg.387]

Exhibit 6.6 Phase III Study A Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Dosing in Antiretroviral-Experienced, HIV-1 Infected Subjects... [Pg.185]

The purpose of this study is to determine whether once-daily dosing of the lopinavir/ritonavir (Kaletra) tablet in combination with investigator-selected nucleoside/nucleotide reverse transcriptase inhibitors will reduce HIV viral load to very low levels in patients who have detectable viral loads with their current antiretroviral therapy. [Pg.185]

Based on HIV-1 drug resistance genotypic test results at the Screening Visit and prior treatment history, the investigator considers lopinavir/ritonavir plus at least two NRTIs to be an appropriate treatment for the subject. [Pg.186]

Subject does not require and agrees not to take any antiretroviral medication except lopinavir/ritonavir and NRTIs. [Pg.186]

HIV treatment In combination with other antiretroviral agents for the treatment of HIV infection. This indication is based on analyses of plasma HIV RNA levels and CD4 cell counts in a controlled study of lopinavir/ritonavir combination of 24 weeks duration and in smaller uncontrolled dose-ranging studies of 72 weeks duration. At present, there are no results from controlled trials evaluating the effect on clinical progression of HIV. [Pg.1830]

Therapy-naive patients-The recommended dosage is 400/100 mg of lopinavir/ritonavir (3 capsules or 5 mL taken with food, or 2 tablets taken with or without food) twice daily or 800/200 mg of lopinavir/ritonavir (6 capsules or 10 ml taken with food, or 4 tablets with or without food) once daily. [Pg.1831]

Concomitant therapy with efavirenz, nevirapine, fosamprenavir, or nelfinavir-Consider a dose increase to 533/133 mg lopinavir/ritonavir (4 capsules or 6.5 mL) twice daily taken with food when used in combination with efavirenz, nevirapine, amprenavir, or nelfinavir, or 600/150 mg (3 tablets) twice daily with or without food when used in combination with efavirenz, nevirapine, fosamprenavir without ritonavir, or nelfinavir in treatment-experienced patients where decreased susceptibility to lopinavir is clinically suspected (by treatment history or laboratory evidence). [Pg.1831]

Children (6 months to 12 years of age) The recommended dosage of lopinavir/ritonavir oral solution is 12/3 mg/kg for those weighing 7 to less than 15 kg and 10/2.5 mg/kg for those 15 to 40 kg (approximately equivalent to 230/57.5 mg/m ) twice daily with food, up to a maximum dose of 400/100 mg in children greater than 40 kg (5 mL or 3 capsules, or 2 tablets) twice daily. It is preferred that the prescriber calculate the appropriate milligram dose for each individual child 12 years of age and younger and determine the corresponding volume of solution or number of capsules or tablets. [Pg.1831]

Lopinavir/Ritonavir Pediatric Dosage Without Efavirenz or Nevirapine... [Pg.1831]

Dosing based on the lopinavir component of lopinavir/ritonavir solution (80 mg/20 mg per ml). [Pg.1832]

Administration - Lopinavir/ritonavir tablets may be taken with or without food capsules and oral solution must be taken with food. Tablets should be swallowed whole and not chewed, broken, or crushed. [Pg.1833]

Pharmacology Lopinavir, an HIV protease inhibitor, prevents cleavage of the Gag-Pol polyprotein, resulting in the production of immature, noninfectious viral particles. As coformulated in the lopinavir/ritonavir combination, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, providing increased lopinavir plasma levels. [Pg.1833]

Absorption - Administration of a single 400/100 mg dose of lopinavir/ritonavir... [Pg.1833]

Metabolism - Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme. Ritonavir is a potent CYP3A inhibitor that inhibits the metabolism of lopinavir and, therefore, increases plasma levels of lopinavir. Ritonavir has been shown to induce metabolic enzymes, resulting in the induction of its own metabolism. [Pg.1834]

Hepatic function impairment Lopinavir/ritonavir is principally metabolized by the liver therefore, exercise caution when administering this drug to patients with hepatic impairment because lopinavir concentrations may be increased. Consider increased AST/ALT monitoring in these patients, especially during the first several months of lopinavir/ritonavir treatment. [Pg.1834]


See other pages where Lopinavir ritonavir is mentioned: [Pg.122]    [Pg.52]    [Pg.104]    [Pg.107]    [Pg.1255]    [Pg.1259]    [Pg.1267]    [Pg.1275]    [Pg.1276]    [Pg.452]    [Pg.186]    [Pg.1830]    [Pg.1833]    [Pg.1834]    [Pg.1834]   
See also in sourсe #XX -- [ Pg.209 ]

See also in sourсe #XX -- [ Pg.209 ]

See also in sourсe #XX -- [ Pg.223 ]

See also in sourсe #XX -- [ Pg.396 ]

See also in sourсe #XX -- [ Pg.209 ]

See also in sourсe #XX -- [ Pg.1219 , Pg.1223 ]




SEARCH



Lopinavir

Lopinavir/ritonavir , protease

Lopinavir/ritonavir , protease inhibitor

Lopinavir/ritonavir adverse effects

Lopinavir/ritonavir dosage

Lopinavir/ritonavir drug interactions

Rifabutin lopinavir + ritonavir

Rifampicin lopinavir + ritonavir

Ritonavir and lopinavir Oral Solution

© 2024 chempedia.info